The DOI matches its Crossref record.
Very Early Nimodipine Use in Stroke (VENUS): A Randomized, Double-Blind, Placebo-Controlled Trial
Abstract
Backgound and Purpose —The Very Early Nimodipine Use in Stroke (VENUS) trial was designed to test the hypothesis that early treatment with nimodipine has a positive effect on survival and functional outcome after stroke. This was suggested in a previous meta-analysis on the use of nimodipine in stroke. However, in a recent Cochrane review we were unable to reproduce these positive results. This led to the early termination of VENUS after an interim analysis. Methods —In this randomized, double-blind, placebo-controlled trial, treatment was started by general practitioners or neurologists within 6 hours after stroke onset (oral nimodipine 30 mg QID or identical placebo, for 10 days). Main analyses included comparisons of the primary end point (poor outcome, defined as death or dependency after 3 months) and secondary end points (neurological status and blood pressure 24 hours after inclusion, mortality after 10 days, and adverse events) between treatment groups. Subgroup analyses (on final diagnosis and based on the per-protocol data set) were performed. Results —At trial termination, after inclusion of 454 patients (225 nimodipine, 229 placebo), no effect of nimodipine was found. After 3 months of follow-up, 32% (n=71) of patients in the nimodipine group had a poor outcome compared with 27% (n=62) in the placebo group (relative risk, 1.2; 95% CI, 0.9 to 1.6). A treatment effect was not found for secondary outcomes and in the subgroup analyses. Conclusions —The results of VENUS do not support the hypothesis of a beneficial effect of early nimodipine in stroke patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Jauch, E. C., Saver, J. L., Adams, H. P., Bruno, A., Connors, J. J. (., Demaerschalk, B. M., Khatri, P., McMullan, P. W., Qureshi, A. I., Rosenfield, K., et al. (2013) · Stroke · doi:10.1161/str.0b013e318284056a · Cited by 7,634
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2018) · Stroke · doi:10.1161/str.0000000000000158 · Cited by 5,446
Adams, H. P., del Zoppo, G., Alberts, M. J., Bhatt, D. L., Brass, L., Furlan, A., Grubb, R. L., Higashida, R. T., Jauch, E. C., Kidwell, C., et al. (2007) · Stroke · doi:10.1161/strokeaha.107.181486 · Cited by 2,475
Adams, H. P., del Zoppo, G., Alberts, M. J., Bhatt, D. L., Brass, L., Furlan, A., Grubb, R. L., Higashida, R. T., Jauch, E. C., Kidwell, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181486 · Cited by 904
Neuroprotection for ischemic stroke: Past, present and future
Ginsberg, M. D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.007 · Cited by 779
Sandset, E. C., Bath, P. M., Boysen, G., Jatuzis, D., Kõrv, J., Lüders, S., Murray, G. D., Richter, P. S., Roine, R. O., Terént, A., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60104-9 · Cited by 541
HYPOXIC-ISCHEMIC ENCEPHALOPATHY
Vannucci, R. (2000) · American Journal of Perinatology · doi:10.1055/s-2000-9293 · Cited by 524
Neuroprotection for ischemic stroke: Two decades of success and failure
Cheng, Y. D., Al-Khoury, L., & Zivin, J. A. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.36 · Cited by 384
Potter, J. F., Robinson, T. G., Ford, G. A., Mistri, A., James, M., Chernova, J., & Jagger, C. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70263-1 · Cited by 331
The Optimising Analysis of Stroke Trials (OAST) Collaboration (2007) · Stroke · doi:10.1161/strokeaha.106.474080 · Cited by 192
Weaver, C. S., Leonardi-Bee, J., Bath-Hextall, F. J., & Bath, P. M. W. (2004) · Stroke · doi:10.1161/01.str.0000125010.70652.93 · Cited by 67
Metadata
- Authors
- Horn, J., de Haan, R. J., Vermeulen, M., & Limburg, M.
- Venue
- Stroke
- Published
- 2001-02
- Volume
- 32
- Issue
- 2
- Pages
- 461-465
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2141722155
- Cited by
- 168
- References
- 0
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.